The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmakodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study.
 
Bjorn T. Gjertsen
Leadership - Alden Cancer Therapy II; Kinn Therapeutics
Stock and Other Ownership Interests - Alden Cancer Therapy II; Kinn Therapeutics
Consulting or Advisory Role - BerGenBio; Novartis; Seagen
Research Funding - Boehringer Ingelheim
Patents, Royalties, Other Intellectual Property - Alden Cancer Therapy II patent application in relation to CryoIT trial.
Travel, Accommodations, Expenses - Novartis; Seagen
 
Monica Hellesøy
No Relationships to Disclose
 
Håkon Reikvam
No Relationships to Disclose
 
Astrid Olsnes Kittang
No Relationships to Disclose
 
David Micklem
Employment - BerGenBio
Leadership - BerGenBio
Stock and Other Ownership Interests - BerGenBio
Patents, Royalties, Other Intellectual Property - BerGenBio
 
Anthony Brown
Employment - BerGenBio
Stock and Other Ownership Interests - BerGenBio
 
James Lorens
Employment - BerGenBio
Leadership - BerGenBio
Stock and Other Ownership Interests - BerGenBio
Research Funding - BerGenBio (Inst)
Patents, Royalties, Other Intellectual Property - BerGenBio
Travel, Accommodations, Expenses - BerGenBio
 
Maxim Kebenko
No Relationships to Disclose
 
Melanie Janning
No Relationships to Disclose
 
Mascha Binder
No Relationships to Disclose
 
Walter M. Fiedler
No Relationships to Disclose
 
Jorge E. Cortes
Consulting or Advisory Role - Amphivena Therapeutics; Astellas Pharma; Bio-Path Holdings, Inc; BiolineRx; Bristol-Myers Squibb; Daiichi Sankyo; Novartis; Pfizer; Takeda
Research Funding - Ambit BioSciences (Inst); Arog (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Celator (Inst); Celgene (Inst); Immunogen (Inst); Novartis (Inst); Pfizer (Inst); Sun Pharma (Inst); Takeda (Inst)
 
Michael Heuser
No Relationships to Disclose
 
Jörg Chromik
No Relationships to Disclose
 
Peter Paschka
No Relationships to Disclose
 
Carlos Enrique Vigil
No Relationships to Disclose
 
Sonja Loges
No Relationships to Disclose